Showing 5021-5030 of 6808 results for "".
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Upadacitinib Improves Night-time Itch and Sleep Disturbance: Studyhttps://practicaldermatology.com/news/analysis-upadacitinib-improves-night-time-itch-and-sleep-disturbance/2462217/Researchers publishing the poster at Maui Derm 2024 analyzed integrated data from the Measure Up 1 and Measure Up 2 phase-3 randomized, double-blinded studies looking the safety and efficacy of upadacitinib 15 mg (UPA 1
- FDA Gives Nod to Marketing DermaSensor for Skin Lesion Evaluationhttps://practicaldermatology.com/news/fda-gives-nod-to-dermasensor-for-skin-lesion-evaluation/2462213/The U.S Food and Drug Administration (FDA) announced that it has granted authorization for marketing for the DermaSensor (DermaSensor Inc.) prescription device, indicated for the evaluation of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients ag
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- Skin Deep Solutions: Navigating Acne and Rosacea with Quality Skin Carehttps://practicaldermatology.com/news/skin-deep-solutions-navigating-acne-and-rosacea-with-quality-skin-care/2462209/In the ever-evolving landscape of dermatology, Hilary Baldwin, MD, a board-certified dermatologist, and the medical director of the Acne Treatment & Research Center in Brooklyn, recently shed light on the critical role
- Co-occurring Autistic Spectrum Disorder Mediates ADHD on Atopic Dermatitis, Acnehttps://practicaldermatology.com/news/co-occurring-asd-mediates-impact-of-adhd-on-atopic-dermatitis-and-acne-a-retrospective-cohort-study/2462200/Both male and females who were diagnosed with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) showed different risks for acne and eczema, according to a study. "Our study is the first to examine the association between ASD, ADHD, and two of the most commo
- Study: Patient-reported Methods Can Change PSSD Scores, Enhance Interpretationhttps://practicaldermatology.com/news/meaningful-change-thresholds-for-the-psoriasis-symptoms-and-signs-diary/2462195/A new analysis suggests that Psoriasis Symptoms and Signs Diary (PSSD) improvements of 15, 25, or 30 points are indicative of increasing improvements in disease burden useful to patients who have psoriasis. Researchers writing in
- PF-07038124 Shows Safety, Efficacy for AD and Plaque Psoriasis: Studyhttps://practicaldermatology.com/news/efficacy-and-safety-of-pf-07038124-in-patients-with-atopic-dermatitis-and-plaque-psoriasis/2462191/A novel topical phosphodiesterase 4 inhibitor (PF-07038124) has been shown to be efficacious and well-tolerated in patients with atopic dermatitis (AD) and plaque psoriasis, according to new study results. Researchers writing in
- Can-Fite Receives Positive Response from FDA for Psoriasis Pediatric Planhttps://practicaldermatology.com/news/can-fite-receives-positive-response-from-fda-for-psoriasis-pediatric-plan/2462187/The U.S. Food and Drug Administration (FDA) gave a positive response to a study plan for piclidenoson in children suffering from psoriasis. The plan allows for children to enroll in the phase 3 pivotal clinical study aiming at registering the drug with both the FDA as well as the Europe
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Patients 9 Years and Olderhttps://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-topical-foam-03-for-the-treatment-of-seborrheic-dermatitis-in-patients-9-years-and-older/2462186/Arcutis Biotherapeutics, Inc. announced the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in those 9 years of age and older. ZORYVE foam provides rapid disease clearance and